{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:23:49Z","timestamp":1783347829584,"version":"3.54.6"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We evaluated the role of complete cytoreductive surgery (CRS) for locoregional disease control in patients with colorectal cancer with peritoneal metastases (CRC-PM) and concurrent extraperitoneal metastases (EPM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Institutional data identified patients with CC-0\/1 CRS for CRC-PM. Patients with peritoneal disease only (PDO) were compared with those with concomitant EPM. Co-primary outcomes were progression-free survival (PFS) and peritoneal progression-free survival (p-PFS). The secondary outcome was overall survival (OS). Covariate imbalance was addressed using entropy balancing. Survival was analyzed using a weighted Cox proportional hazards model. Subgroup analyses were performed to identify favorable prognostic groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 83 patients were included: 31 (37.4%) had EPM. Baseline characteristics were comparable. Within the EPM cohort, liver-only metastases were most common (58%), followed by lung-only metastases (26%). EPM were managed at index CRS in 61%, before CRS in 19%, and deferred or untreated in 19% of patients. Unadjusted analyses demonstrated comparable median OS (PDO vs. EPM: 39 vs. 34 months,\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.551) and median p-PFS (PDO vs. EPM: 17 vs. 15 months,\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.346) but longer median PFS in the PDO group (14 vs. 5 months, p&lt;0.001). After entropy balancing, patients with EPM had worse OS (31.6 vs. 38.7 months; hazard ratio [HR] 2.12; 95% confidence interval [CI] 1.02\u20134.37;\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &lt;\u20090.05) and PFS (5.0 vs.12.8 months; HR 2.7; 95% CI 1.58\u20134.5;\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &lt;\u20090.001) but similar p-PFS (13.4 vs.14.9 months; HR 1.10; 95% CI 0.58\u20131.77;\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.622). Subgroup analyses demonstrated comparable OS and p-PFS for patients with PDO and those with single-site liver or lung EPM.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Complete CRS provides durable locoregional disease control in patients with EPM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19750-7","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:28:07Z","timestamp":1778520487000},"page":"7569-7578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Locoregional Control from Complete Peritoneal Cytoreduction in Patients with Extraperitoneal Colorectal Cancer Metastases: An Entropy Balanced Analysis"],"prefix":"10.1245","volume":"33","author":[{"given":"M. Daniyal","family":"Tanweer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac B.","family":"Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thinzar","family":"Lwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laleh","family":"Melstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuman","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep","family":"Brar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pashtoon","family":"Kasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Raoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"3","key":"19750_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"19750_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/jso.20558","volume":"94","author":"NC Bird","year":"2006","unstructured":"Bird NC, Mangnall D, Majeed AW. Biology of colorectal liver metastases: a review. J Surg Oncol. 2006;94(1):68\u201380. https:\/\/doi.org\/10.1002\/jso.20558.","journal-title":"J Surg Oncol."},{"issue":"12","key":"19750_CR3","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 2016;17(12):1709\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(16)30500-9.","journal-title":"Lancet Oncol."},{"issue":"1","key":"19750_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric french study. J Clin Oncol. 2010;28(1):63\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.23.9285.","journal-title":"J Clin Oncol."},{"issue":"6","key":"19750_CR5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/SLA.0b013e31827e9289","volume":"257","author":"D Go\u00e9r\u00e9","year":"2013","unstructured":"Go\u00e9r\u00e9 D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257(6):1065. https:\/\/doi.org\/10.1097\/SLA.0b013e31827e9289.","journal-title":"Ann Surg."},{"issue":"16","key":"19750_CR6","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1002\/cncr.25116","volume":"116","author":"J Franko","year":"2010","unstructured":"Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ III. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756\u201362. https:\/\/doi.org\/10.1002\/cncr.25116.","journal-title":"Cancer."},{"issue":"2","key":"19750_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol."},{"key":"19750_CR8","doi-asserted-by":"publisher","first-page":"101492","DOI":"10.1016\/j.suronc.2020.11.006","volume":"37","author":"JT Wiseman","year":"2021","unstructured":"Wiseman JT, Abdel-Misih S, Beal EW, et al. A multi-institutional analysis of textbook outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. Surg Oncol. 2021;37:101492. https:\/\/doi.org\/10.1016\/j.suronc.2020.11.006.","journal-title":"Surg Oncol."},{"issue":"12","key":"19750_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","volume":"89","author":"DG Jayne","year":"2002","unstructured":"Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. BJS Br J Surg. 2002;89(12):1545\u201350. https:\/\/doi.org\/10.1046\/j.1365-2168.2002.02274.x.","journal-title":"BJS Br J Surg."},{"issue":"1","key":"19750_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10434-004-1167-z","volume":"12","author":"VJ Verwaal","year":"2005","unstructured":"Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FAN. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12(1):65\u201371. https:\/\/doi.org\/10.1007\/s10434-004-1167-z.","journal-title":"Ann Surg Oncol."},{"key":"19750_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jss.2022.04.007","volume":"277","author":"EW Beal","year":"2022","unstructured":"Beal EW, Chen JC, Kim A, et al. Is cytoreductive surgery-hyperthermic intraperitoneal chemotherapy still indicated in patients with extraperitoneal disease? J Surg Res. 2022;277:269\u201378. https:\/\/doi.org\/10.1016\/j.jss.2022.04.007.","journal-title":"J Surg Res."},{"issue":"25","key":"19750_CR12","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1200\/JCO.22.00839","volume":"40","author":"D Rossini","year":"2022","unstructured":"Rossini D, Antoniotti C, Lonardi S, et al. Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients With RAS\/BRAF wild-type metastatic colorectal cancer: the phase III triplete study by GONO. J Clin Oncol. 2022;40(25):2878\u201388. https:\/\/doi.org\/10.1200\/JCO.22.00839.","journal-title":"J Clin Oncol."},{"issue":"7","key":"19750_CR13","doi-asserted-by":"publisher","first-page":"109650","DOI":"10.1016\/j.ejso.2025.109650","volume":"51","author":"A Pawar","year":"2025","unstructured":"Pawar A, Kepenekian V, Omar A, et al. Influence of lung metastases on outcomes of curative management of peritoneal metastases from colorectal cancer. Eur J Surg Oncol. 2025;51(7):109650. https:\/\/doi.org\/10.1016\/j.ejso.2025.109650.","journal-title":"Eur J Surg Oncol."},{"issue":"4","key":"19750_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ctrv.2012.11.003","volume":"39","author":"EMV De Cuba","year":"2013","unstructured":"De Cuba EMV, Kwakman R, Knol DL, Bonjer HJ, Meijer GA, Te Velde EA. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases. Cancer Treat Rev. 2013;39(4):321\u20137. https:\/\/doi.org\/10.1016\/j.ctrv.2012.11.003.","journal-title":"Cancer Treat Rev."},{"key":"19750_CR15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ijsu.2015.11.025","volume":"25","author":"JB Delhorme","year":"2016","unstructured":"Delhorme JB, Dupont-Kazma L, Addeo P, et al. Peritoneal carcinomatosis with synchronous liver metastases from colorectal cancer: Who will benefit from complete cytoreductive surgery? Int J Surg. 2016;25:98\u2013105. https:\/\/doi.org\/10.1016\/j.ijsu.2015.11.025.","journal-title":"Int J Surg."},{"issue":"5","key":"19750_CR16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/SLA.0000000000006492","volume":"280","author":"VJ Dagenborg","year":"2024","unstructured":"Dagenborg VJ, Brudvik KW, Lund-Andersen C, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy and liver resection is a treatment option for patients with peritoneal and liver metastases from colorectal cancer. Ann Surg. 2024;280(5):745. https:\/\/doi.org\/10.1097\/SLA.0000000000006492.","journal-title":"Ann Surg."},{"issue":"4","key":"19750_CR17","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1245\/s10434-023-14840-2","volume":"31","author":"R Grange","year":"2024","unstructured":"Grange R, Rousset P, Williet N, et al. Metastatic colorectal cancer treated with combined liver resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy (hipec): predictive factors for early recurrence. Ann Surg Oncol. 2024;31(4):2378\u201390. https:\/\/doi.org\/10.1245\/s10434-023-14840-2.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"19750_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s13193-016-0505-5","volume":"7","author":"SS Mehta","year":"2016","unstructured":"Mehta SS, Bhatt A, Glehen O. Cytoreductive surgery and peritonectomy procedures. Indian J Surg Oncol. 2016;7(2):139\u201351. https:\/\/doi.org\/10.1007\/s13193-016-0505-5.","journal-title":"Indian J Surg Oncol."},{"issue":"16","key":"19750_CR19","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.3390\/jcm11164922","volume":"11","author":"F Mendoza-Moreno","year":"2022","unstructured":"Mendoza-Moreno F, Diez-Alonso M, Mat\u00edas-Garc\u00eda B, et al. Prognostic factors of survival in patients with peritoneal metastasis from colorectal cancer. J Clin Med. 2022;11(16):4922. https:\/\/doi.org\/10.3390\/jcm11164922.","journal-title":"J Clin Med."},{"key":"19750_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1247-5","volume-title":"Peritoneal carcinomatosis: principles of management","author":"PH Sugarbaker","year":"1996","unstructured":"Sugarbaker PH. Peritoneal carcinomatosis: principles of management. 1st edn. New York: Springer; 1996. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5.","edition":"1"},{"key":"19750_CR21","doi-asserted-by":"publisher","first-page":"101371","DOI":"10.1016\/j.ssmph.2023.101371","volume":"22","author":"N Larrain","year":"2023","unstructured":"Larrain N, Groene O. Improving the evaluation of an integrated healthcare system using entropy balancing: population health improvements in Gesundes Kinzigtal. SSM Popul Health. 2023;22:101371. https:\/\/doi.org\/10.1016\/j.ssmph.2023.101371.","journal-title":"SSM Popul Health."},{"issue":"1","key":"19750_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/pan\/mpr025","volume":"20","author":"J Hainmueller","year":"2012","unstructured":"Hainmueller J. Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies. Polit Anal. 2012;20(1):25\u201346. https:\/\/doi.org\/10.1093\/pan\/mpr025.","journal-title":"Polit Anal."},{"issue":"4","key":"19750_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/pds.4121","volume":"26","author":"RA Harvey","year":"2017","unstructured":"Harvey RA, Hayden JD, Kamble PS, Bouchard JR, Huang JC. A comparison of entropy balance and probability weighting methods to generalize observational cohorts to a population: a simulation and empirical example. Pharmacoepidemiol Drug Saf. 2017;26(4):368\u201377. https:\/\/doi.org\/10.1002\/pds.4121.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"19750_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu260","author":"E Van Cutsem","year":"2024","unstructured":"Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2024. https:\/\/doi.org\/10.1093\/annonc\/mdu260.","journal-title":"Ann Oncol"},{"issue":"1","key":"19750_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000454687","volume":"33","author":"JW Holch","year":"2017","unstructured":"Holch JW, Demmer M, Lamersdorf C, et al. Pattern and dynamics of distant metastases in metastatic colorectal cancer. Visc Med. 2017;33(1):70\u20135. https:\/\/doi.org\/10.1159\/000454687.","journal-title":"Visc Med."},{"issue":"15","key":"19750_CR26","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-2581","volume":"19","author":"CG Smith","year":"2013","unstructured":"Smith CG, Fisher D, Claes B, et al. Somatic profiling of the epidermal growth factor receptor pathway in tumours from patients with advanced colorectal cancer, treated with chemotherapy \u00b1 cetuximab. Clin Cancer Res. 2013;19(15):4104\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2581.","journal-title":"Clin Cancer Res."},{"issue":"12","key":"19750_CR27","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/s41416-022-01742-5","volume":"126","author":"J Laoukili","year":"2022","unstructured":"Laoukili J, Constantinides A, Wassenaar ECE, et al. Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity. Br J Cancer. 2022;126(12):1824\u201333. https:\/\/doi.org\/10.1038\/s41416-022-01742-5.","journal-title":"Br J Cancer."},{"issue":"8","key":"19750_CR28","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S1470-2045(12)70210-3","volume":"13","author":"PH Sugarbaker","year":"2012","unstructured":"Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol. 2012;13(8):e362\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(12)70210-3.","journal-title":"Lancet Oncol."},{"issue":"3","key":"19750_CR29","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/annonc\/mdt591","volume":"25","author":"N Hugen","year":"2014","unstructured":"Hugen N, van de Velde CJH, de Wilt JHW, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014;25(3):651\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdt591.","journal-title":"Ann Oncol."},{"key":"19750_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103990","volume":"186","author":"C Carconi","year":"2023","unstructured":"Carconi C, Cerreti M, Roberto M, et al. The management of oligometastatic disease in colorectal cancer: present strategies and future perspectives. Crit Rev Oncol Hematol. 2023;186:103990. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103990.","journal-title":"Crit Rev Oncol Hematol."},{"issue":"3","key":"19750_CR31","doi-asserted-by":"publisher","first-page":"e0122816","DOI":"10.1371\/journal.pone.0122816","volume":"10","author":"G D\u00e9solneux","year":"2015","unstructured":"D\u00e9solneux G, Mazi\u00e8re C, Vara J, et al. Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLoS ONE. 2015;10(3):e0122816. https:\/\/doi.org\/10.1371\/journal.pone.0122816.","journal-title":"PLoS ONE."},{"issue":"9","key":"19750_CR32","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/DCR.0000000000001156","volume":"61","author":"D Baratti","year":"2018","unstructured":"Baratti D, Kusamura S, Iusco D, et al. Should a history of extraperitoneal disease be a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer peritoneal metastases? Dis Colon Rectum. 2018;61(9):1026. https:\/\/doi.org\/10.1097\/DCR.0000000000001156.","journal-title":"Dis Colon Rectum."},{"issue":"17","key":"19750_CR33","doi-asserted-by":"publisher","first-page":"LBA3502","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA3502","volume":"42","author":"AA Adhin","year":"2024","unstructured":"Adhin AA, Bakkerus L, Zonderhuis BM, et al. Primary outcome analysis of the ORCHESTRA trial: A randomized phase III trial of additional tumor debulking to first-line palliative systemic therapy for patients with multiorgan metastatic colorectal cancer. J Clin Oncol. 2024;42(17):LBA3502. https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA3502.","journal-title":"J Clin Oncol."},{"issue":"8","key":"19750_CR34","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s11605-022-05390-1","volume":"26","author":"A Pantelis","year":"2022","unstructured":"Pantelis A, Ben-Yaacov A, Adileh M, et al. Outcomes of stable lung colorectal metastases on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Gastrointest Surg. 2022;26(8):1724\u201331. https:\/\/doi.org\/10.1007\/s11605-022-05390-1.","journal-title":"J Gastrointest Surg."},{"issue":"7","key":"19750_CR35","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1245\/s10434-023-13279-9","volume":"30","author":"F Schell","year":"2023","unstructured":"Schell F, Kefleyesus A, Benzerdjeb N, et al. Influence of extraperitoneal metastases on the curative-intent management of colorectal peritoneal metastases. Ann Surg Oncol. 2023;30(7):4444\u201354. https:\/\/doi.org\/10.1245\/s10434-023-13279-9.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19750-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19750-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19750-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:36:46Z","timestamp":1783345006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19750-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["19750"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19750-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Marwan Fakih\u2014Consulting or Advisory services: AbbVie, Adagene Inc, Astellas Pharma, Bayer Corporation, Bristol Myers Squibb, Delcath Systems, Inc, Exelixis, Inc, GSK, Iterion Therapeutics, Inc, Janssen Research and Development, Merck, Merus NV, Microbial Machines, Mirati Therapeutics, Inc., Pfizer Inc., Revolution Medicines, Inc, Roche\/ Genentech, Summit Therapeutics Inc, Taiho Oncology, Tempus, Totus Medicines Inc., Xilio Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}